Physician profile
Megan Eichmeier
NPI 1437645272
$717.71
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.59 · 2022: $22.82 · 2023: $281 · 2024: $79.50 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $130.69 | 2021-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $88.17 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.41 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.73 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $68.77 | 2021-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $56.83 | 2025 | Cobenfy |
| Corium, LLC | $44.08 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $37.47 | 2023 | Trintellix |
| Axsome Therapeutics, INC. | $35.99 | 2023-2025 | Auvelity |
| Alkermes, INC. | $30.27 | 2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $17.86 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $17.42 | 2025 | Austedo Xr |
| Almatica Pharma LLC | $14.02 | 2021 | |
| Neurocrine Biosciences, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Eichmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.